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ABSTRAK (VERSI BAHASA MELAYU) 
 
PENGENALAN : 
Rheumatoid arthritis (Radang sendi) merupakan penyakit kronik yang kebanyakannya 
menyerang sendi-sendi dan tisu-tisu sekitar, dan turut menyerang struktur lain dalam badan 
manusia. Ia akan menyebabkan kemusnahan kepada tulang dan juga tulang rawan seterusnya 
menyebabkan pesakit mengalami kecacatan yang kekal. Selain ‘rheumatoid factor’, anti-citrate 
citrullinated peptide antibody (‘anti-CCP antibody’) merupakan satu ujian yang baru 
diperkenalkan, yang dapat digunakan untuk mengesahkan diagnosis ini  malah dikatakan lebih 
tepat berbanding ujian-ujian lain.  
 
OBJEKTIF : 
Tujuan kajian ini ialah untuk menilai keberkesanan dan potensi ‘anti-CCP antibody’ dalam 
menentukan tahap keaktifan dan progres penyakit terutama dalam kontek radiologi dan 
penglibatan struktur badan yang lain selain sendi, semasa diagnosis RA dibuat melibatkan 
pesakit rheumatoid arthritis dalam populasi HUSM. 
 
KAEDAH : 
Kajian ini merupakan kajian ‘cross sectional with retrospective record review’. Seramai 159 
orang pesakit yang disahkan menghidap penyakit ‘rheumatoid  arthritis’ berdasarkan ‘2010 
ACR/EULAR Rheumatoid Arthritis Classification Criteria’ dari tahun 2010 hingga 2017 yang 
sedang menerima rawatan di Klinik Rheumatologi di HUSM diterima masuk dalam kajian ini. 
Pesakit berumur kurang daripada 16 tahun semasa diagnosis, ‘probable RA’, dan ‘overlap 
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syndromes’ atau penyakit radang yang lain dikecualikan daripada kajian ini. Data dikumpul 
daripada rekod perubatan untuk ‘rheumatoid factor’, ‘anti-CCP antibody’, penilaian aktiviti 
penyakit melalui skor ‘DAS-28 ESR’, x-ray tangan dan kaki dan penilaian untuk ‘rheumatoid 
nodule’, penyakit paru-paru, ‘Felty syndrome’, ‘vasculitis’ dan penyakit kurang darah merah 
semasa diagnosis dilakukan. 
 
KEPUTUSAN : 
Daripada 159 pesakit, 134 orang (84.3%) merupakan perempuan, dengan majority etnik adalah 
Melayu (87.4%). Purata umur ialah 48.3 tahun; iaitu di antara 17 hingga 79 tahun. ‘Prevalence 
‘anti-CCP antibody’ adalah 52.2% (95% CI 0.44 hingga 0.60) manakala peratus untuk 
‘rheumatoid factor’ ialah 62.3%. Purata markah DAS28-ESR untuk keseluruhan pesakit ialah 
4.74 di mana untuk peratusan kumpulan penilaian aktiviti penyakit, kebanyakan pesakit 
terletak dalam kumpulan sederhana dan tinggi. 36.5% pesakit menunjukkan perubahan pada 
ujian radiologi manakala 30.8% pesakit pula mempunyai tanda-tanda ‘extra-articular’ iaitu 
‘rheumatoid nodule’, penyakit paru-paru, dan kurang darah merah.  
Pesakit yang menunjukkan keputusan yang positif dalam ujian ‘rheumatoid factor’ dan ‘anti-
CCP antibody’ adalah lebih ramai berbanding pesakit yang menunjukkan keputusan yang 
berbeza (n=83; 73.5%) (p-value 0.002). Untuk penilaian melibatkan ‘anti-CCP antibody’ 
positif dan negatif, Perubahan radiologi didapati lebih tinggi di dalam kumpulan ‘anti-CCP 
antibody’ positif berbanding kumpulan ‘anti-CCP antibody’ negative. Namun,.didapati tiada 
perbezaan ketara antara purata dan kumpulan penilaian aktiviti penyakit, dan tanda-tanda 
‘extra-articular’. Tiada perbezaan di antara tahap ‘disease activity’ yang berbeza dan tanda-
tanda ‘extra-articular’.  
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KESIMPULAN : 
Sebagai kesimpulan, pesakit yang mempunyai ‘anti-CCP antibody’ positif didapati mempunyai 
kaitan yang ketara dengan ‘rheumatoid factor’ dan perubahan radiologi, tetapi tidak 
menunjukkan sebarang perbezaan ketara dalam tahap keaktifan penyakit dan tanda-tanda 
‘extra-articular’ semasa pesakit didiagnosis sebagai rheumatoid arthritis.  
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ABSTRACT (ENGLISH VERSION)  
 
BACKGROUND : 
Rheumatoid arthritis (RA) is a chronic debilitating inflammatory disease affecting mainly the 
joint and surrounding tissue, and also involved other extra articular structures in the body. It 
can lead to destruction of bone and cartilage which may cause severe disability to the patient. 
Other than rheumatoid factor, anti-cyclic citrullinate peptide (anti-CCP) antibody is another 
biomarker that can be used to diagnose RA with higher sensitivity and specificity.   
 
OBJECTIVE :  
To evaluate the significant of anti-CCP antibody in predicting the disease activity, and disease 
progression in term of radiological and extra articular manifestation upon diagnosis in patient 
with rheumatoid arthritis in HUSM. 
 
METHODS : 
This was a cross sectional study with retrospective record review. A total of 159 patients who 
were diagnosed as rheumatoid arthritis based on 2010 EULAR criteria for RA since 2010 until 
2017 under rheumatology clinic HUSM follow up were included in this study. Exclusion 
criteria include age of 16 years old or less at the onset of diagnosis, probable RA, and overlap 
syndromes or related to other connective tissue disease. The data was retrieved from medical 
record for rheumatoid factor, anti-CCP antibody, assessment of disease activity using DAS28 
ESR calculator, plain radiograph of hands or feet, and extra-articular manifestation in term of 
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assessment of rheumatoid nodule, pulmonary involvement, Felty syndrome, vasculitis and 
anemia upon diagnosis. 
 
RESULTS : 
From a total of 159 patients, 134 (84.3%) patients were female with majority ethnic group was 
Malay (87.4%). The mean for age was 48.3 years old; ranging from 17 to 79.  The prevalence 
of anti-CCP antibody was 52.2% (95% CI 0.44 to 0.60) and the percentage of positive 
rheumatoid factor was 62.3%. Mean DAS28-ESR score for total patients was 4.74 which 
medium and high disease activity were predominant upon diagnosis. 36.5% of patients had 
radiological involvement and 30.8% of patients had extra-articular involvement manifested by 
rheumatoid nodule, pulmonary involvement, and anemia.  
Patients with both positive rheumatoid factor and anti-CCP antibody was significantly higher 
than other groups (n=83; 73.5%) (p-value 0.002). For radiological involvement, it was 
significantly higher in anti-CCP antibody positive group. However, there was no significant 
difference between mean and classes of disease activity score, and extra-articular 
manifestations between different anti-CCP antibody positivity group. Extra-articular 
manifestations was not associated with high disease activity upon diagnosis of RA. 
 
CONCLUSION : 
In conclusion, there was significant association between anti-CCP antibody positivity and 
positive rheumatoid factor and radiological involvement, however no significant difference 
found in mean disease activity and extra-articular manifestation upon diagnosis in patient with 
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RA in HUSM. Extra-articular manifestations was not associated with high disease activity upon 
diagnosis of RA. 
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CHAPTER ONE 
INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic debilitating inflammatory disease affecting 
mainly the joint and surrounding tissue. It is characterized by chronic inflammatory 
process in the synovium which is caused by infiltration by the immune and inflammatory 
cells; particularly macrophages, B- and T-lymphocytes, dendritic cells and plasma cells. 
This process leads to increase in the levels of cytokines which contains destructive 
enzymes, specifically matrix metalloproteinase (Feldman et al., 1996). As a result, 
sustained recruitment, inappropriate retention and impaired apoptosis may occur which 
can cause destruction of the bone, cartilage and soft tissue and subsequently leads to 
severe disability to the patient (Morovic et al., 2003). The etiology or precipitating factor 
of this disease is unknown; however interaction between both genetic and environmental 
factors are said to contribute to its occurrence (Alamanos et al., 2005).  RA is a systemic 
disease, in which can also involve variety of extra-articular organs such as lung, eye, 
vessels, blood cells and many others. Early and aggressive intervention with establish or 
even new drugs can reduce the pathogenic process, improve the function of the joint, and 
increase the quality of life (Niewold et al., 2007).  
RA is affecting approximately 0.5% to 1% of the world population based on the 
geographical distribution and ethnically diverse population (Gabriel et al., 2009). In 
2010, Egyptian Society for Rheumatology had reported the prevalence of RA was 0.1%, 
in comparison to previous study more than 10years ago in Northwest Greece by Drosos 
et al., (1997) which showed the prevalence of 0.2%. On the other hand, the majority of 
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studies carried out in Northern European and North American areas estimate a higher 
prevalence rate of 0.5 to 1%, and a mean annual incidence of 0.02-0.05% (Alamanos et 
al., 2005).  Female was found to be affected higher than male (Drosos et al., 1997, 
Carmona et al., 2003). 
 
1.1 Pathophysiology of Rheumatoid Arthritis 
The pathogenesis of RA is not well understood. Some theories suggest autoimmune 
reaction triggered by an external circumstance such as trauma, smoking, infection, or 
stress, leading to inflammation of the synovial membrane. Inflammatory cells and 
cytokines play a major roles in the pathophysiology of RA. CD4 T cells, mononuclear 
phagocytes, osteoclasts, neutrophils, and fibroblast may infiltrate the synovial tissue 
while together with abnormal cytokines, chemokines and other inflammatory mediators 
such as tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-6, 
transforming growth factor beta (TGF-β), fibroblast growth factor (FGF) and platelet-
derived growth factor (PDGF), cause destruction of various tissues including cartilage, 
bones, tendons, ligaments and blood vessels. 
Angiogenesis also contributes to the development of chronic inflammation and plays an 
important role in the pathogenesis of RA (Eker et al., 2014). Vascular endothelial growth 
factor (VEGF) has been detected to be present in very large amounts in the inflammatory 
synovium in RA. Various studies showed that both VEGF and macrophage migration 
inhibitory factor (MIF) are associated with disease activity parameters and with each 
other in RA 
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It is believed that genetic factors also contributed to the formation of RA (Alamanos et 
al., 2005). A family history of RA increases the risk around three to five times; as of 2016 
it was estimated that genetics factors may account for between 40 and 65% of cases of 
seropositive RA, but only around 20% for seronegative RA. 
Smoking is the strongest known environmental risk factor for RA especially in Caucasian 
populations. It is increasing the risk three times compared to non-smokers, particularly 
in men. This association was first described over a decade ago but has been further 
characterized recently with the use of anti-CCP antibody assay. A recent study found that 
tobacco smoking was specifically associated with an increased risk of ACPA-positive 
and not ACPA-negative RA. As the majority of RA patients who are ACPA positive are 
also rheumatoid factor positive, these findings concur with previous studies which show 
an overall risk of RA for smokers, specifically for rheumatoid factor-positive RA 
(Katherine et al, 2009). The risk of RA increases with amount and duration of cigarette 
use. Findings from a large prospective cohort study, the Nurses’ Health Study (NHS), 
showed a linear relationship between smoking and risk of RA whereby increasing doses 
of cigarettes (pack-years of smoking) was associated with an increased risk of RA. The 
heaviest smokers with more than 40 pack-years had approximately two-fold increase of 
risk for RA than those who had never smoked. Furthermore, an individual remains at 
increased risk even after cessation for 20 years or more. 
Silica exposure has been linked to RA. A recent review of the epidemiologic evidence of 
environmental factors in human autoimmune diseases concluded that exposure to 
crystalline silica contributes to the development of a number of autoimmune diseases, 
including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic 
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sclerosis, and anti-neutrophil cytoplasmic antibody (ANCA) related vasculitis (Pollard 
K. M., 2016)  
 
1.2 Clinical Presentation Of Rheumatoid Arthritis 
The hallmark feature of rheumatoid arthritis is the symmetrical polyarthritis involving 
small joints of hands or feet. A patient may complaint of pain and stiffness of the joints 
especially early in the morning which usually improve after movement. The number of 
joints involved is variable; it can be either single small joint involvement at first then 
spread to another joints, and typically affected more than five joints. Any synovial joint 
can become involved in RA. The joints most frequently involve are metacarpophalangeal 
joint (MCPJ) and proximal interphalangeal joint (PIPJ) of the hands, wrist, and small 
joints of the feet including the metatarsophalangeal joints (MTP). Sparing of the distal 
interphalangeal joints (DIPJ) is the most characteristic feature of RA. Though presented 
often in textbooks as features of ‘swan neck’ and ‘boutonniere’ deformity of the digits, 
it appears late in disease and is a feature of chronic disease. They are not usually seen at 
initial presentation where signs of synovitis and joint damage may be subtle. Swan neck 
deformity is a condition which the DIPJ is flexed while PIPJ is hyperextended. 
Boutonniere deformity occur when there is flexion of PIPJ with hyperextension of DIPJ. 
Another features that often found in RA patients is “Z-thumb" or "Z-deformity" of the 
thumb. It consists of hyperextension of the interphalangeal joint, fixed flexion 
and subluxation of the metacarpophalangeal joints and gives a "Z" appearance to the 
thumb. Not to forget other joints involvement such as elbows, shoulders, knees, and also 
the hips and temporomandibular joints. RA also affects the clavicular joints and the crico-
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arytenoid joints. A mono- or bilateral arthropathy of the shoulder or wrist may account 
for up to 30 to 40% of initial presentations while 5% of initial presentations involve the 
knee.  
The pain and stiffness may lead to difficulty in performing activities of daily living 
(ADL) such as combing hair, turning the doorknob, dressing, or even walking. A patient 
who already has deformity of the hand performs worse.  Acute inflammatory arthritis is 
reversible, and it is very important to detect it early to prevent chronic inflammation 
which can cause severe irreversible disability which may affect their ADL. In addition to 
these, nonspecific systemic symptoms such as myalgia, fatigue, fever, reduce in appetite 
and loss of weight may also present. RA usually has insidious onset of symptoms. Initial 
symptoms can be systemic or mild arthritis without significant interruption in daily 
activity before the appearance of overt joint pain and swelling.  
 
1.3 Diagnosis of Rheumatoid Arthritis 
1.3.1 1987 ACR Classification Criteria of Rheumatoid Arthritis 
In 1956, a committee of the American Rheumatism Association (ARA) had proposed a 
criteria for the diagnosis of RA. From this criteria, eleven components had been 
identified. This criteria had been revised few times in 1958, 1966, and 1983 to improve 
the sensitivity and specificity of the criteria in order to aid in the diagnosis and 
management of RA.  
The revised criteria for the classification of RA (Arnett et al., 1988) was published in 
1987. There were a total of seven component in this criteria, listed as follows: 1) morning 
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stiffness in and around the joints lasting at least one hour before maximal improvement; 
2) soft tissue swelling (arthritis) of three or more joint areas observed by a physician; 3) 
swelling (arthritis) of the PIPJ, MCPJ, or wrist joints; 4) symmetrical swelling (arthritis); 
5) rheumatoid nodules; 6) presence of rheumatoid factor; and 7) radiographic erosions 
and/or peri articular osteopenia in hand and/or wrist joints. Criteria 1 to 4 must have been 
present for at least 6 weeks. To diagnose RA, a patient must have at least 4 or more 
criteria, and no further classifications (eg: classic, definite, or probable) are required. This 
criteria had demonstrated 91% to 94% sensitivity and 89% specificity for RA subject in 
comparison to non-RA control subjects. 
Symptoms of early morning stiffness for at least one hour represent inflammatory process 
that accumulate much more while the joint is less mobile. Total joint involvement must 
be more than three, which most of the time is symmetrical and typically involve small 
joint of the hands or feet compared to larger joints.  Rheumatoid factor is the only 
laboratory test included in this criteria while rheumatoid nodule is the only extra-articular 
manifestation that is required. For radiological changes, the expected finding includes 
erosions or unequivocal bony decalcification localized in the involved joints. Over the 
last decades, this 1987 classification criteria is well accepted as a benchmark for disease 
definition, however it had been criticized for lack of sensitivity in diagnosing early 
disease (Aletaha et al., 2010). This criteria had been recognized for the diagnosis of 
establish RA but unable to discriminate those who are in early disease whom would 
benefit from early intervention especially with the raised of biologic agents.  
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1.3.2 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria 
In order to facilitate the diagnosis of early RA, American Colleges of Rheumatology 
(ACR) and the European League against Rheumatism (EULAR) had been joining hand 
to form a working group in order to develop a new classification criteria for RA. Hence, 
in 2010, this new ACR/EULAR Rheumatoid Arthritis Classification criteria had been 
introduced (Aletaha et al., 2010). In this new criteria, it redefines RA on the condition at 
earlier stages, compared to the previous 1987 ACR criteria that predict more of erosive 
disease.  
2010 ACR/EULAR classification criteria for RA had classify definite RA based on four 
main categories; A) joint involvement; B) serological test; C) acute phase reactants and 
D) duration of symptom. Patients who need to be tested must have at least one joint 
involvement with definite clinical synovitis, and has no other alternative diagnosis to 
explain the synovitis. Definite RA is confirmed by having a score of 6 or more from a 
total score of 10. In this criteria, the first domain calculate the number and site of joint 
involvement either small or large joint which give a score of 0 to 5, while second domain 
is comprise of serological test such as rheumatoid factor or anti-CCP antibody assay 
based on titre with the score of 0 to 3. The third domain include acute phase reactant 
which is either Erythrocyte Sedimentation Rate (ESR) or C - Reactive Protein (CRP) that 
give a score of 1 if positive and 0 if negative. Fourth domain is about the duration of 
symptoms; with the score of one for duration of 6 weeks or more.    
In comparison with the 1987 ACR criteria, the 2010 ACR/EULAR criteria have higher 
sensitivity but lower specificity, especially in patients aged 60 years or more. 
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1.3.3 Rheumatoid Factor 
Rheumatoid factor is the immunoglobulin M (IgM) autoantibody against denatured 
immunoglobulin G (IgG) Fc fragment which is secreted by B cells and can be found 
circulating in the blood. About 60–80% RA patients had positive rheumatoid factor 
during the course of their disease (Nell V.P. et al, 2005). However, rheumatoid factor 
results were positive in less than 40% of patients with early RA. Rheumatoid factor is 
also present with other connective-tissue diseases, autoimmune disorders, and pro-
inflammatory states such as systemic lupus erythematosus (SLE), polymyositis, 
tuberculosis, syphilis, viral hepatitis and many others. It is also observed in 1-5% of 
healthy individuals and can be found up to 20% in older population. Thus, rheumatoid 
factor is not considered specific for RA. 
The normal reference range for RF is less than 15 IU/mL or less than 1:16. 
Rheumatoid factor had been use as the only serological marker for the diagnosis of 
rheumatoid arthritis since many years. It has assumed a pivotal role in subcategorizing 
patients into ‘seropositive’ and ‘seronegative’ groups, despite incomplete knowledge of 
the role of rheumatoid factor in disease pathogenesis, its frequent absence in early stages 
of disease, its suppression by disease modifying drugs and its occurrence in hidden form. 
In patients with rheumatoid arthritis,  some studies showed that RA patients with positive 
rheumatoid factor had higher proportion of complicated with extra-articular 
manifestations, had more aggressive  radiological progress, and had worse prognosis than 
the RF-negative RA (Edelman et al, 1983 ). Greiner and colleagues (2005) followed up 
135 RA patients for 6 years and the result showed that the disease activity was higher in 
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the persistent RF-positive group, and the patients need more intensive treatment in the 
persistent RF-positive group than the persistent RF-negative group. 
 
1.3.4 Anti Cyclic Citrullinated Peptide Antibody 
The introduction of anti-CCP antibody assay as a new serological marker for RA is a 
significant advance in rheumatological field. Anti-CCP antibody is principally an 
autoantibodies directed to citrullinated proteins in the synovium of patients with RA 
(Szekanecz et al., 2008). The first citrulline-binding autoantibodies in RA sera were 
discovered by Nienhuis et al. in 1964, and were named as anti-perinuclear factor. In 1979, 
Young et al. found that RA sera contained anti-keratin antibodies that reacted to the 
keratinized layer of epithelium. Uniquely these antibodies were only found in patients 
who had been diagnosed with RA. Subsequent studies demonstrated that anti-keratin 
antibodies and anti-perinuclear factor recognized a similar epitope, and therefore, can be 
categorized as anti citrullinated peptide antibodies (Niewold et al., 2007). Subsequently, 
anti-CCP 1 assay was made commercially available followed by the second generation 
of anti-CCP 2 assay that was made using combination of synthetic cyclic citrullinated 
peptides selected through a screening process. It was built to increase the sensitivity over 
anti-CCP 1 antibody while maintaining the specificity (Taylor et al., 2011). Now anti-
CCP 2 antibody assay is been used widely in the diagnosis of RA.  
Many studies had been done to assess the effectiveness of this new serology marker in 
the diagnosis of RA and also in the progression of the disease, either related to the disease 
activity or in the prognostication of RA. The sensitivity and specificity of anti-CCP 
antibody for the diagnosis of rheumatoid arthritis (RA) were 66.0% and 90.4%, 
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respectively (Niewold et al., 2007). In an early arthritis study, which was conducted in 
The Netherlands, Jansen et al (2002) found that having values of IgM rheumatoid factor 
more than 40 or anti-CCP of more than 50 predicts which patients with early arthritis will 
be diagnose as RA with a sensitivity of 55.4% and a specificity of 96.7%. Saraux et al 
(2003) studied two hundred and seventy patients with early arthritis and found anti-CCP 
antibody sensitivity of 47% and specificity of 93%. Anti-CCP antibody was proven to be 
useful in identifying those with significant disease activity and more severe radiological 
outcome (van der Helm-Van Mil et al., 2005., Chou et al., 2007).  
The reference ranges for blood test for anti-CCP antibody are negative if less than 20 EU, 
low or weak positive if ranging between 20 to 39 EU, moderate positive if fall in range 
of 40 to 59 and high or strong positive if the level is more than 60 EU. 
 
1.4 Assessment Of Disease Activity  
In daily clinical practice, assessment of disease activity is important especially to 
determine the requirement for treatment. There are many criteria that can be used to 
determine patient’s disease activity but out of 63 criteria, ACR had recommended six 
with the best psychometric properties. The criteria recommended by ACR are Patient 
Activity Scale (PAS), Patient Activity Scale II (PAS-II), Routine Assessment of Patient 
Index Data with 3 measures (RAPID 3), Clinical Disease Activity Index (CDAI), Disease 
Activity Score with 28-joint counts (ESR or CRP) (DAS-28 ESR or CRP), and Simplified 
Disease Activity Index (SDAI). All these criteria had been chosen as they accurately 
reflex the disease activity, categorized well in different states of remission, mild, 
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moderate and high disease activity, and easy to perform in clinical setting. The aim of 
treatment is to get patients into remission or at least mild disease activity. 
The DAS28 is an index similar to the original DAS, modified from the original 44 joint 
count in DAS index into simplified 28 tender and swollen joint count (range 0-28), 
ESR, and an optional general health assessment on a visual analogue scale (range 0-
100). Because of the use of reduced and non-graded joint counts, the DAS28 is easier to 
complete than the DAS. The DAS28 has a continuous scale ranging from 0 to 9.4, and 
usually shows a Gaussian distribution in RA populations. DAS and DAS28 values 
cannot be directly compared, but a formula to transform DAS28 into DAS values is 
available. This is important especially in research purposes.  
Disease activity had been studied widely in relationship with serology markers like 
rheumatoid factor and anti-CCP antibody. Many studies showed anti-CCP antibody titres 
are positively correlated with the disease activity (Drosos et al., 1997, Kastbom et al., 
2004) 
 
1.5 Radiological Manifestation of Rheumatoid Arthritis 
Other than plain radiograph, there are few other imaging modalities available to assess 
the radiographic progression in RA patient. Magnetic Resonance Imaging (MRI) have 
the capability to image the joint in great detail and is more sensitive than other modalities 
to detect joint inflammation and destruction. However, the main disadvantages is it is 
quite expensive especially for monitoring as it need to be done from time to time, 
regularly. Furthermore, it also has no standardize scoring method available between 
different centres. Ultrasonography can detect early synovitis by detection of effusion, 
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synovial hypertrophy, and signal from power Doppler, other than bony erosion and 
cartilage thickness. It is easy to be used in clinical setting and become more popular 
nowadays among rheumatologist. The main disadvantages include inability to assess 
certain sites due to acoustic window and because it is operator dependent, it requires 
training for a significant period of time.  
Plain radiograph, although seems to be old fashion compared to these newer modalities, 
is still the investigation of choice as it is readily available, cheap and easy to perform. 
Assessment of structural damage to look for bony erosion and joint space narrowing may 
suggest establish disease and failure to detect early changes makes plain radiograph less 
favourable. One large cohort study showed that radiographically demonstrable erosions 
were present in 30% of patients at diagnosis, and in 70% three years later support the 
importance of this modalities in identifying establish RA disease. The radiographic 
hallmarks of rheumatoid arthritis are soft tissue swelling, which are fusiform and 
periarticular to represents a combination of joint effusion, oedema and tenosynovitis, 
osteoporosis which initially juxta-articular, and later generalised; compounded by 
corticosteroid therapy and disuse, joint space narrowing which can either symmetrical or 
concentric, and marginal erosions due to erosion by pannus of the bony bare areas. In the 
hands, a patient can demonstare late changes such as subchondral cyst, subluxation 
causing ulnar deviation of the MCPJ, swan neck deformity and boutonniere’s deformity, 
hitchhiker’s thumb deformity, carpal instability manifested by scapholunate dissociation 
and ulnar translocation, and ankylosis.  
From most of the study, they found that RA patients with positive anti-CCP antibody 
have more radiographic joint damage as compared to those without these antibodies 
(Meyer et al., 2003, Forslind et al., 2004).  
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1.6 Extra Articular Manifestation  
Although joint surface is the primary site involved, tissues in the body other than the joint 
can still be affected. It can manifest as rheumatoid nodule, vasculitic lesion, pulmonary 
involvement, pericarditis, peripheral neuropathy, benign lymphadenopathy or 
haematological manifestation like anemia. The frequency of extra-articular manifestation 
is difficult to estimate. Most studies have been performed at highly specialized centres, 
with poorly defined catchment areas. Population studies of extra-articular manifestation 
on the other hand, are difficult to perform since they require uniform and consistent 
ascertainment of such complications in a defined catchment area population (Turesson et 
al, 1999).  
Extra articular manifestation can develop at any time during the course of the disease, 
even in the early stages. Extra articular manifestation of RA are thought to be particularly 
frequent in severe, active disease. They are known as a serious condition and has been 
shown to be associated with significant morbidity and high mortality.  
 
1.6.1 Rheumatoid Nodule 
Rheumatoid nodule is the most frequent skin manifestation of RA, occur in about 20-
30% of RA patients (Vela et al., 2014, Cojocaru et al., 2010). It has variable consistency, 
but usually rather firm to touch. The nodule is related to poor prognostic factor and almost 
exclusively occur in rheumatoid factor positive patient (Richman et al., 2013, Cojocaru 
et al., 2010). It is most commonly seen on pressure area such as olecranon process and 
proximal ulna, but can also be seen in finger joints, occiput, sacral prominences and 
Achilles tendon. Rarely does it occurs in the main organ of the body such as the lung, 
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heart valves, or at diverse sites on body (e.g. upper eyelid, distal region of the soles of 
the feet, vulva and internally in the gallbladder, larynx, and spine). The occurrence of 
nodules in the lung of miners exposed to silica dust was known as Caplan’s Syndrome. 
About 5% of RA patients have such nodules within two years of disease onset. In the 
great majority of cases nodules are not painful or disabling in any way, being more of an 
unsightly nuisance, but in some cases they can be painful, especially if the overlying skin 
breaks down. 
 
1.6.2 Pulmonary involvement 
Pulmonary involvement in RA can be manifested in few different ways, includes 
parenchymal pulmonary nodules, pleural effusion, interstitial lung disease (ILD), 
pulmonary vasculitis and small airway disease. Pulmonary nodules are usually 
asymptomatic, but can cause cavitation and had increased risk of infection. ILD is the 
most important pulmonary manifestation of RA, as it leads to high morbidity and 
mortality. It is among the commonest pulmonary cause of death in RA. Types of ILD 
that most commonly occur are usual interstitial pneumonia (UIP) (44% to 56%), non-
specific interstitial pneumonia (NSIP) (33% to 44%), mixed disease (0% to 12%) and 
obliterative bronchiolitis. Pathophysiology related to this pulmonary manifestation is by 
early inflammatory phase associated with pulmonary mononuclear cell infiltrates which 
later form a fibrosis. This condition usually occur in male patient with positive 
rheumatoid factor and had long standing nodular disease. Clinical presentations are 
similar to idiopathic pulmonary fibrosis but the respond to immunosuppressant is usually 
better. Diagnosis must be based on clinical presentation, blood gases, lung function test, 
15 
 
and high resolution computed tomography (HRCT) or lung biopsy. Six minute walking 
test is a simple bedside test that can be done if a patient is suspected to have this 
pulmonary involvement. 
 
1.6.3 Felty Syndrome 
Felty syndrome is defined as combination of RA with splenomegaly and neutropenia. It 
is a rare disease which usually occur less than 1% in elderly woman at the age of around 
60. It is usually associated with severe long standing articular disease and also positive 
rheumatoid factor and anti-CCP antibody. In most patient with Felty Syndrome, other 
extra-articular features such as lymphadenopathy, hepatomegaly, vasculitis and leg ulcer 
will also present. Felty syndrome can lead to severe infection due to neutropenia which 
can be recurrent, and sometimes fatal. A careful evaluation should be made before the 
diagnosis of Felty Syndrome being made to exclude other malignant haematological 
causes of neutropenia; with the fact that this syndrome has been associated with an 
increased risk of malignant lympho proliferative disease. The clinical significant of Felty 
syndrome is commonly was not driven so much attention as it usually occur during 
inactive disease of RA. 
 
1.6.4 Anemia 
Anemia is among the most common haematological changes presents in patient with RA. 
It is mostly related to anemia of chronic illness, which is normocytic normochromic type 
of anemia, but can also occur as secondary to other causes. Decreased iron absorption 
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was shown to be the result of active RA rather than a cause of anemia of chronic disease 
or iron deficiency anemia. It has been hypothesized that iron availability in the bone 
marrow decreases due to decreased in iron release by the mononuclear phagocyte system. 
Another postulation is that the anemia in anemia of chronic diseae is due to ineffective 
erythropoiesis, however these remain controversial theories. Studies considering a 
decreased erythropoietin responsiveness have not produced consistent results. Erythroid 
colony growth is suppressed in vitro by interleukins 1 and interleukin 6 and tumour 
necrosis factor alpha but their role in vivo in anemia of chronic disease is unknown. The 
diagnosis of anemia of chronic disease is made by exclusion. Iron deficiency is detected 
by transferrin, ferritin, and cellular indices after adaptation of their normal values. This 
is proven by a study by Papadaki et al (2002), saying that treatment with anti-TNF 
therapies results in significant improvement in the anemia associated RA. 
 
1.6.5 Cutaneous vasculitis 
Vasculitis in RA can manifested in many organs including skin, neuron, or specific organ 
vasculitis such as renal or pulmonary. The most common manifestation of cutaneous 
vasculitis are small digital infarction along the nail bed, skin ulcerations or gangrene. As 
is true with other forms of vasculitis that involve the skin, cutaneous lesions can erupt on 
various areas of the body in RV, with a predilection for the lower extremities. Typical 
findings include ulcers concentrated near the ankles. The manifestations of RV in other 
body’s different organ systems, including peripheral nervous system is manifested as 
numbness to the hands and feet, while arteries of the fingers and toes involvement can 
cause digital ischemia, and eyes involvement are typically with scleritis. This vasculitic 
17 
 
lesion is related to the deposition of immune complexes intravascularly by rheumatoid 
factor and immunoglobulins, which leads to damage and destruction to the vessels. The 
syndrome usually emerges after years of seropositive RA which is persistently in active 
disease. However, vasculitis can also occur when joints are in inactive state. 
 
1.6.6 Other extra-articular manifestation of RA 
There are many other signs of extra-articular involvement that can be elicited in a patient 
with RA related to any organ in the body. Ocular involvement occurs in 27% of RA 
patients. Keratoconjunctivitis of Sjogren’s syndrome is the most common benign eye 
manifestation that presented as dry eyes (sicca). Episcleritis may occur occasionally with 
the main complaint of mild pain and intense redness of the eye. Scleritis and corneal 
ulcerations are rare but requires urgent attention and treatment with DMARDS. Schirmer 
test is a simple bedside test that can be done for screening of dry eyes.  
Sjogren’s syndrome occur in approximately 10-15% of RA patients. It is a chronic 
inflammatory disorder that affects exocrine gland function especially lacrimal and 
salivary gland. It leads to reduction of tear (keratoconjunctivitis sicca), dry mouth 
(xerostomia) and reduce vaginal secretions.  
Cardiovascular manifestation in RA patients include pericarditis, myocarditis, cardiac 
amyloidosis, coronary vasculitis, arrhythmia, valve disease and most importantly 
ischemic heart disease and congestive cardiac failure. The last two diseases has high 
mortality risk in RA patient in comparison to general population. RA is associated with 
a 1.5-fold increased incidence of coronary heart disease (CHD), stroke, total 
cardiovascular disease, fatal cardiovascular disease, and total mortality. The 
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pathogenesis is said to be related to acceleration in the atherogenesis that cannot be 
explained by the classical risk of atherosclerosis. Despite improved treatment, there is 
little evidence of reduction in coronary heart disease or cardiovascular morbidity or 
mortality. Risk factors for incident of coronary heart disease in RA include traditional 
cardiovascular disease risk factors (e.g., cigarette smoking, hypertension, diabetes 
mellitus, and elevated low-density lipoprotein cholesterol) and markers of RA severity, 
including inflammatory markers (e.g., ESR and CRP), joint pain, and disability. 
Pericarditis is also common, occur in 1% to 4% of patients especially those with positive 
rheumatoid factor.  
The most common neurological manifestation of RA is primary sensory peripheral 
neuropathy, which is usually mild and involved lower extremities. This nerve damage 
can cause foot or wrist drop, as a cause of mononeuritis multiplex. This condition, which 
may be significantly disabling, is often preceded by a change in sensation in the same 
area which can be either numbness, tingling, burning, or pain. These abnormal sensations 
can progress to muscle weakness, focal paralysis, and eventually to muscle wasting. 
Recovery from this condition, caused by nerve infarction, can take months. In some 
cases, recoveries from mononeuritis multiplex are incomplete. Other neurological 
manifestations include cervical myelopathy, vasculitis, and nodule within the central 
nervous system, meningitis or stroke.  
Nephropathy in RA can occur due to various causes. Several potential causes that had 
been identified are drug induce, renal amyloidosis, and various type of 
glomerulonephritis. Gold or penicillamine can cause membranous type of 
glomerulonephritis. Other medications such as non-steroidal anti-inflammatory drugs 
(NSAIDs), sulphasalazine or methotrexate were also found to cause serious adverse 
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effect especially in patient with underlying kidney disease. Renal involvement in RA is 
clinically meaningful because it worsen the course of primary disease and increases 
mortality.  
 
1.7 Management of Rheumatoid Arthritis 
The goals of treatment in rheumatoid arthritis include reduction in joint pain and 
inflammation, prevention of joint destruction or permanent damage and the most 
important thing is the improvement in the quality of life. The principle of treating 
rheumatoid arthritis is based on treat-to-target recommendation as proposed by 2014 
Update of the Recommendations of an International Task Force (Smolen et al., 2015). 
The target for the treatment is remission or low disease activity in every follow up which 
are proven as the best and second best outcome in RA. 
Disease-modifying anti-rheumatic drugs (DMARDs) is a group of medication that is 
widely used as the primary agent for the treatment of RA. These agents are capable of 
slowing down the disease progression thus able to improve patient’s quality of life. 
DMARDs can be divided into synthetic chemical compounds DMARDs (sDMARDs) 
and biological agent DMARDs (bDMARDs). Methotrexate is the most commonly used 
agent for sDMARDs other than sulfasalazine, hydroxychloroquine and leflonamide, 
whereas tofacitinib is a new agent targeting Janus kinases.  
Although originally designed as a chemotherapy drug (using high doses), in low doses, 
methotrexate is a generally safe and well tolerated drug in the treatment of certain 
autoimmune diseases. Because of its effectiveness, low-dose methotrexate is now first-
line therapy for the treatment of rheumatoid arthritis. Weekly doses are beneficial for 12 
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to 52 weeks duration therapy, although discontinuation rates are as high as 16% due to 
adverse effects. Although methotrexate for autoimmune diseases is taken in lower doses 
than it is for cancer, side effects such as hair loss, nausea, headaches, and skin 
pigmentation are still common. Use of low doses of methotrexate together with NSAIDS 
such as aspirin or analgesics such as paracetamol is relatively safe in people being treated 
for rheumatoid arthritis, if adequate monitoring is done. 
Methotrexate toxicity can lead to stomatitis, gastro intestinal disturbance, and also 
alopecia. This effect can be reduced by the addition of folic acid daily, without loss of 
therapeutic effect. Parenteral administration is a useful option if oral treatment is not 
tolerated, and there is also some evidence that parenteral administration can improved 
the efficacy of methotrexate compared with oral administration. Another rare but 
important complication of methotrexate are pneumonitis and pulmonary fibrosis. These 
complications should not deter the physician from using methotrexate in aggressive 
systemic and skeletal disease. Rare, life-threatening, pulmonary toxicity can occur at any 
time but is most common in the first year and is not directly related to dose or duration 
of treatment. A chest radiograph should be taken before methotrexate is commenced. 
Mild drug-induced hepatitis is relatively common and is often corrected by the addition 
of folic acid. Liver function abnormalities fluctuate and may require the drug to be 
stopped for a short period if transaminase levels rise above 2–3 times the upper limit of 
normal, with possible re-introduction after a period of time when levels have normalized, 
with close monitoring. Patients are advised that they should abstain from alcohol use 
completely.  
Sulfasalazine and hydroxychloroquine are often used initially in mild RA, partly because 
of their relative safety and convenience. Both agents are generally well-tolerated and take 
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effect within 1 to 3 months. Many clinicians now choose MTX first if there is evidence 
of early aggressive disease. Leflunomide is also effective for the treatment of RA. It is 
an inhibitor of the enzyme dihydro-orotate dehydrogenase and shows anti-proliferative 
activity, inhibiting pyrimidine synthesis. It has a long half-life of 2 weeks. 
IM and oral steroids are very effective in active RA, reducing active disease in an acute 
crisis or while waiting for a DMARD to take effect. 
Biological DMARDs consist of TNF inhibitor such as adalimumab, certolizumab pegol, 
etanercept, golimumab and infliximab, T cell costimulation inhibitors such as abatacept, 
anti-B cell agent such as rituximab, interleukin-6 receptor blocking monoclonal antibody 
such as tocilizumab and interleukin-1 inhibitor such as anakinra. With all the above anti-
TNF-α agents, co-administration with methotrexate is recommended when tolerated as 
this has been shown to increase efficacy, and use with infliximab also reduces the 
production of anti-infliximab and antinuclear antibodies. Another type of agent that had 
been recently approved by the European Medicines Agency (EMA) is a biosimilar type 
of DMARD, for example is the biosimilar infliximab (bs-infliximab). This agent may 
help in reducing the treatment costs associated with biologics. 
Damage to joints, with associated pain and loss of function remains a familiar feature of 
chronic RA. Surgical intervention may have a place in such situations, although certain 
procedures such as shoulder replacement may only be effective in reducing pain and may 
not necessarily improve the joint function. Synovectomy is less frequently performed 
now, although tenosynovectomy is common, and a quick and safe relief of nerve 
entrapment. Other common surgical procedures include decompression of the carpal 
tunnel, reconstructive arthroplasty of hip and knee which less often done if involve the 
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shoulder, elbow, and small joints of the hand, corrective arthrotomies of the metatarsals, 
stabilization of the cervical spine and tendon release and transfer and also arthrodesis, 
particularly of the ankle joint.  
 
1.8 Prognosis 
Identification of poor prognostic factors in RA patient is important as it may help in 
providing appropriate and adequate treatment to the patient in order to prevent further 
complication. Intervention with DMARDs in early RA may help in retarding progression 
to joint destruction. Few conditions associated with unfavourable prognosis are HLA-
DRB 1 genotype, high titre of rheumatoid factor and anti-CCP antibody, onset at younger 
age which is usually less than 30years old, female, high number of joint involvement, 
insidious onset of symptom, and presence of extra-articular manifestations. Other 
markers that are related to poor prognosis are early radiological involvement, presence 
of anemia and antikeratin antibodies.  
RA gives rise to higher morbidity and mortality rates; it cause 60% of the patients with 
RA unable to work after 10 years (Quinn et al., 2005). The development of extra–articular 
manifestation in RA patients can have significant impact on their daily activity, including 
increased mortality compared to RA patients in general. That is the reason why early 
detection of RA and early treatment is very crucial in order to prevent devastating 
deformity. 
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1.9 Study Background and Rationale 
Anti-CCP antibody has not been used widely in most of the centre in Malaysia. Many 
physician still depends on rheumatoid factor to diagnose RA. This is most likely because 
they do not understand and see the importance of this assay in the diagnosis and 
management of RA. Because of this, we are not only missed the chance to detect patient 
with early disease, we also unable to prognosticate them and overlooked those whom 
would benefit from early intervention especially with the raised of biologic agents. In 
this study, we want to prove that anti-CCP antibody had significant importance in 
different aspect of disease activity, radiological involvement, and extra-articular 
manifestation in the diagnosis of RA. We sought to assess the efficacy of this anti-CCP 
antibody in patient with RA and also assess the association between variety of 
presentation upon diagnosis so that anti-CCP antibody assay can be utilized as optimum 
as possible. 
Extra-articular manifestation was not being investigate thoroughly in our daily practice. 
Many extra-articular manifestation were misdiagnosed as other disease not related to RA 
because they can develop at any time during the course of the disease, even in the early 
stages. Furthermore, there were not many studies done in Malaysia assessing the 
importance of this assay particularly in the occurrence of extra-articular manifestation. 
Other than that, in this study, we also wanted to assess the association between extra-
articular manifestation and disease activity upon diagnosis. 
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CHAPTER TWO 
OBJECTIVE AND RESEARCH QUESTIONS 
 
2.1 General Objective  
To evaluate the significant of anti-CCP antibody in predicting disease activity and disease 
progression upon diagnosis in patient with rheumatoid arthritis in HUSM. 
 
2.2 Specific Objectives  
2.2.1 To determine the prevalence of patient with positive anti-CCP antibody in RA 
population in HUSM.  
2.2.2 To determine the association between anti-CCP antibody and rheumatoid factor 
in RA patients in HUSM. 
2.2.3 To compare the mean of DAS28 disease activity score in RA patients with 
positive and negative anti-CCP antibody upon diagnosis. 
2.2.4 To determine the association between DAS28 classes of disease activity, 
radiological involvement and extra-articular manifestation in RA patients with 
anti-CCP antibody positivity upon diagnosis. 
2.2.5 To determine the association between disease activity and extra-articular 
manifestations in patient with RA upon diagnosis. 
 
 
